William Chuk Kit Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William Chuk Kit Ng has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Arnaud Romeo Mbadjeu Hondjeu
University of Ottawa, Ottawa, ON, Canada
2 shared publications Azad Mashari
University Health Network
2 shared publications- Azad Mashari
Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada
2 shared publications Dmitry Rozenberg
University Health Network
2 shared publicationsJessica Trac
Affiliation Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsKate Kazlovich
University of Toronto
2 shared publications
Latest Publications
- Open Access
- 14 May 2021
- Published by Springer Nature in Research Square
A reusable, locally manufactured, half- face respirator provides better protection than fitted disposable N95 masks: development and quantitative fit-testing comparison
The COVID-19 pandemic has led to persistent supply shortages of respiratory protective equipment in many jurisdictions. Reusable industrial respirators have been proposed and deployed as an alternative, but also face severe supply limitations. In addition, industrial respirators do not filter the user’s expired breath, a major limitation in health care settings where bidirectional protection is required. We present the development and quantitative testing of a reusable silicone respirator that can be locally manufactured using low-cost desktop infrastructure. Using standardized quantitative fit-testing (QNFT including resting and activity components according to CSA Z94.4-18) in a cohort of 41 healthcare workers (HCWs), we compared the performance of the mask to the individually-fitted disposable N95 masks that the HCWs had been assigned by our institution. Overall QNFT pass rates for disposable N95 respirators were 58.5% vs. 100% for the reusable mask. For a production run of 1000 masks, unit cost is approximately $25 CAD in materials and 35 minutes in labor per mask. The device requires further testing to assess flow resistance, carbon dioxide rebreathing, and full conformance with technical standards required for regulatory approval.
- 14 May 2021
- Published by Springer Nature in Research Square
Open AccessA reusable, locally manufactured, half- face respirator provides better protection than fitted disposable N95 masks: development and quantitative fit-testing comparison
The COVID-19 pandemic has led to persistent supply shortages of respiratory protective equipment in many jurisdictions. Reusable industrial respirators have been proposed and deployed as an alternative, but also face severe supply limitations. In addition, industrial respirators do not filter the user’s expired breath, a major limitation in health care settings where bidirectional protection is required. We present the development and quantitative testing of a reusable silicone respirator that can be locally manufactured using low-cost desktop infrastructure. Using standardized quantitative fit-testing (QNFT including resting and activity components according to CSA Z94.4-18) in a cohort of 41 healthcare workers (HCWs), we compared the performance of the mask to the individually-fitted disposable N95 masks that the HCWs had been assigned by our institution. Overall QNFT pass rates for disposable N95 respirators were 58.5% vs. 100% for the reusable mask. For a production run of 1000 masks, unit cost is approximately $25 CAD in materials and 35 minutes in labor per mask. The device requires further testing to assess flow resistance, carbon dioxide rebreathing, and full conformance with technical standards required for regulatory approval.
- Open Access
- 17 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0247575
Development, manufacturing, and preliminary validation of a reusable half-face respirator during the COVID-19 pandemic
Introduction: The COVID-19 pandemic has led to widespread shortages of N95 respirators and other personal protective equipment (PPE). An effective, reusable, locally-manufactured respirator can mitigate this problem. We describe the development, manufacture, and preliminary testing of an open-hardware-licensed device, the “simple silicone mask” (SSM). Methods: A multidisciplinary team developed a reusable silicone half facepiece respirator over 9 prototype iterations. The manufacturing process consisted of 3D printing and silicone casting. Prototypes were assessed for comfort and breathability. Filtration was assessed by user seal checks and quantitative fit-testing according to CSA Z94.4–18. Results: The respirator originally included a cartridge for holding filter material; this was modified to connect to standard heat-moisture exchange (HME) filters (N95 or greater) after the cartridge showed poor filtration performance due to flow acceleration around the filter edges, which was exacerbated by high filter resistance. All 8 HME-based iterations provided an adequate seal by user seal checks and achieved a pass rate of 87.5% (N = 8) on quantitative testing, with all failures occurring in the first iteration. The overall median fit-factor was 1662 (100 = pass). Estimated unit cost for a production run of 1000 using distributed manufacturing techniques is CAD $15 in materials and 20 minutes of labor. Conclusion: Small-scale manufacturing of an effective, reusable N95 respirator during a pandemic is feasible and cost-effective. Required quantities of reusables are more predictable and less vulnerable to supply chain disruption than disposables. With further evaluation, such devices may be an alternative to disposable respirators during public health emergencies. The respirator described above is an investigational device and requires further evaluation and regulatory requirements before clinical deployment. The authors and affiliates do not endorse the use of this device at present.
- 17 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0247575
Open AccessDevelopment, manufacturing, and preliminary validation of a reusable half-face respirator during the COVID-19 pandemic
Introduction: The COVID-19 pandemic has led to widespread shortages of N95 respirators and other personal protective equipment (PPE). An effective, reusable, locally-manufactured respirator can mitigate this problem. We describe the development, manufacture, and preliminary testing of an open-hardware-licensed device, the “simple silicone mask” (SSM). Methods: A multidisciplinary team developed a reusable silicone half facepiece respirator over 9 prototype iterations. The manufacturing process consisted of 3D printing and silicone casting. Prototypes were assessed for comfort and breathability. Filtration was assessed by user seal checks and quantitative fit-testing according to CSA Z94.4–18. Results: The respirator originally included a cartridge for holding filter material; this was modified to connect to standard heat-moisture exchange (HME) filters (N95 or greater) after the cartridge showed poor filtration performance due to flow acceleration around the filter edges, which was exacerbated by high filter resistance. All 8 HME-based iterations provided an adequate seal by user seal checks and achieved a pass rate of 87.5% (N = 8) on quantitative testing, with all failures occurring in the first iteration. The overall median fit-factor was 1662 (100 = pass). Estimated unit cost for a production run of 1000 using distributed manufacturing techniques is CAD $15 in materials and 20 minutes of labor. Conclusion: Small-scale manufacturing of an effective, reusable N95 respirator during a pandemic is feasible and cost-effective. Required quantities of reusables are more predictable and less vulnerable to supply chain disruption than disposables. With further evaluation, such devices may be an alternative to disposable respirators during public health emergencies. The respirator described above is an investigational device and requires further evaluation and regulatory requirements before clinical deployment. The authors and affiliates do not endorse the use of this device at present.
- Open Access
- 13 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0242304
Subject validation of reusable N95 stop-gap filtering facepiece respirators in COVID-19 pandemic
Introduction: The COVID-19 pandemic has unveiled widespread shortages of personal protective equipment including N95 respirators. Several centers are developing reusable stop-gap respirators as alternatives to disposable N95 respirators during public health emergencies, using techniques such as 3D-printing, silicone moulding and plastic extrusion. Effective sealing of the mask, combined with respiratory filters should achieve 95% or greater filtration of particles less than 1um. Quantitative fit-testing (QNFT) data from these stop-gap devices has not been published to date. Our team developed one such device, the “SSM”, and evaluated it using QNFT. Methods: Device prototypes were iteratively evaluated for comfort, breathability and communication, by team members wearing them for 15-30min. The fit and seal were assessed by positive and negative pressure user seal checks. The final design was then formally tested by QNFT, according to CSA standard Z94.4–18 in 40 volunteer healthcare providers. An overall fit-factor >100 is the passing threshold. Volunteers were also tested by QNFT on disposable N95 masks which had passed qualitative fit testing (QLFT) by institutional Occupational Health and Safety Department. Results: The SSM scored 3.5/5 and 4/5 for comfort and breathability. The median overall harmonic mean fit-factors of disposable N95 and SSM were 137.9 and 6316.7 respectively. SSM scored significantly higher than disposable respirators in fit-test runs and overall fit-factors (p <0.0001). Overall passing rates in disposable and SSM respirators on QNFT were 65% and 100%. During dynamic runs, passing rates in disposable and SSM respirators were 68.1% and 99.4%; harmonic means were 73.7 and 1643. Conclusions: We present the design and validation of a reusable N95 stop-gap filtering facepiece respirator that can match existent commercial respirators. This sets a precedence for adoption of novel stop-gap N95 respirators in emergency situations.
- 13 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0242304
Open AccessSubject validation of reusable N95 stop-gap filtering facepiece respirators in COVID-19 pandemic
Introduction: The COVID-19 pandemic has unveiled widespread shortages of personal protective equipment including N95 respirators. Several centers are developing reusable stop-gap respirators as alternatives to disposable N95 respirators during public health emergencies, using techniques such as 3D-printing, silicone moulding and plastic extrusion. Effective sealing of the mask, combined with respiratory filters should achieve 95% or greater filtration of particles less than 1um. Quantitative fit-testing (QNFT) data from these stop-gap devices has not been published to date. Our team developed one such device, the “SSM”, and evaluated it using QNFT. Methods: Device prototypes were iteratively evaluated for comfort, breathability and communication, by team members wearing them for 15-30min. The fit and seal were assessed by positive and negative pressure user seal checks. The final design was then formally tested by QNFT, according to CSA standard Z94.4–18 in 40 volunteer healthcare providers. An overall fit-factor >100 is the passing threshold. Volunteers were also tested by QNFT on disposable N95 masks which had passed qualitative fit testing (QLFT) by institutional Occupational Health and Safety Department. Results: The SSM scored 3.5/5 and 4/5 for comfort and breathability. The median overall harmonic mean fit-factors of disposable N95 and SSM were 137.9 and 6316.7 respectively. SSM scored significantly higher than disposable respirators in fit-test runs and overall fit-factors (p <0.0001). Overall passing rates in disposable and SSM respirators on QNFT were 65% and 100%. During dynamic runs, passing rates in disposable and SSM respirators were 68.1% and 99.4%; harmonic means were 73.7 and 1643. Conclusions: We present the design and validation of a reusable N95 stop-gap filtering facepiece respirator that can match existent commercial respirators. This sets a precedence for adoption of novel stop-gap N95 respirators in emergency situations.
- 1 September 2020
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 34 (9) , 2539-2541
Pro: Early Extubation After Pediatric Cardiac Surgery
- 1 September 2020
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 34 (9) , 2539-2541
Pro: Early Extubation After Pediatric Cardiac Surgery
- Open Access
- 1 May 2020
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 2 (5) , e0118
Personalized Ventilation to Multiple Patients Using a Single Ventilator: Description and Proof of Concept
Objectives: To design and test a ventilator circuit that can be used for ventilation of two or more patients with a single ventilator, while allowing individualization of tidal volume, fractional concentration of oxygen, and positive end-expiratory pressure to each patient, irrespective of the other patient’s respiratory system mechanics. Design: Description and proof of concept studies. Settings: Respiratory therapy laboratory. Subjects: Ventilation of mechanical test lungs. Interventions: Following a previously advocated design, we used components readily available in our hospital to assemble two “bag-in-a-box” breathing circuits. Each patient circuit consisted of a flexible bag in a rigid container connected via one-way valve to a test lung, along with an inline positive end-expiratory pressure valve, connected to the ventilator’s expiratory limb. Compressed gas fills the bags during “patient” exhalation. During inspiration, gas from the ventilator, in pressure control mode, enters the containers and displaces gas from the bags to the test lungs. We varied tidal volume, “respiratory system” compliance, and positive end-expiratory pressure in one lung and observed the effect on the tidal volume of the other. Measurements and Main Results: We were able to obtain different tidal volume, dynamic driving pressure, and positive end-expiratory pressure in the two lungs under widely different compliances in both lungs. Complete obstruction, or disconnection at the circuit connection to one test lung, had minimal effect (< 5% on average) on the ventilation to the co-ventilated lung. Conclusions: A secondary circuit “bag-in-the-box” system enables individualized ventilation of two lungs overcoming many of the concerns of ventilating more than one patient with a single ventilator.
- 1 May 2020
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 2 (5) , e0118
Open AccessPersonalized Ventilation to Multiple Patients Using a Single Ventilator: Description and Proof of Concept
Objectives: To design and test a ventilator circuit that can be used for ventilation of two or more patients with a single ventilator, while allowing individualization of tidal volume, fractional concentration of oxygen, and positive end-expiratory pressure to each patient, irrespective of the other patient’s respiratory system mechanics. Design: Description and proof of concept studies. Settings: Respiratory therapy laboratory. Subjects: Ventilation of mechanical test lungs. Interventions: Following a previously advocated design, we used components readily available in our hospital to assemble two “bag-in-a-box” breathing circuits. Each patient circuit consisted of a flexible bag in a rigid container connected via one-way valve to a test lung, along with an inline positive end-expiratory pressure valve, connected to the ventilator’s expiratory limb. Compressed gas fills the bags during “patient” exhalation. During inspiration, gas from the ventilator, in pressure control mode, enters the containers and displaces gas from the bags to the test lungs. We varied tidal volume, “respiratory system” compliance, and positive end-expiratory pressure in one lung and observed the effect on the tidal volume of the other. Measurements and Main Results: We were able to obtain different tidal volume, dynamic driving pressure, and positive end-expiratory pressure in the two lungs under widely different compliances in both lungs. Complete obstruction, or disconnection at the circuit connection to one test lung, had minimal effect (< 5% on average) on the ventilation to the co-ventilated lung. Conclusions: A secondary circuit “bag-in-the-box” system enables individualized ventilation of two lungs overcoming many of the concerns of ventilating more than one patient with a single ventilator.
- 17 November 2017
- Published by Springer Nature in Journal of Anesthesia
- Vol. 32 (1) , 54-61
Population analysis of predictors of difficult intubation with direct laryngoscopy in pediatric patients with and without thyroid disease
There are no data on the prevalence and predictors of difficult intubation (DI) in pediatric patients with thyroid disease. This study (1) assesses the prevalence of DI in patients with thyroid disease undergoing elective operations, (2) identifies other predictors of DI in children, and (3) evaluates the effect of DI on postoperative care and length-of-stay.
- 17 November 2017
- Published by Springer Nature in Journal of Anesthesia
- Vol. 32 (1) , 54-61
Population analysis of predictors of difficult intubation with direct laryngoscopy in pediatric patients with and without thyroid disease
There are no data on the prevalence and predictors of difficult intubation (DI) in pediatric patients with thyroid disease. This study (1) assesses the prevalence of DI in patients with thyroid disease undergoing elective operations, (2) identifies other predictors of DI in children, and (3) evaluates the effect of DI on postoperative care and length-of-stay.
- 26 October 2017
- Published by Wiley
- p. 1-19
Metabolism and Toxicity of Inhalational General Anesthetics ( IGA )
Inhaled general anesthetics (IGA) undergo metabolism, biotransformation, and chemical breakdown that can generate toxic substances. Modern IGA are metabolized minimally compared to early generations of IGA and hence are more safe. Pharmacogenomics, age, gender, drug‐drug interaction, concomitant liver and kidney diseases can affect the metabolism and toxicity of IGA. Products of IGA metabolism can rarely induce immune‐mediated hepatotoxicity. Nephrotoxicity of IGA is related to inorganic fluoride, a product of IGA metabolism. There is growing evidence for the neurotoxicity of IGA, especially in the developing or immature brain. Lastly, IGA has complex interactions with the immune system, which may adversely affect susceptible patients.
- 26 October 2017
- Published by Wiley
- p. 1-19
Metabolism and Toxicity of Inhalational General Anesthetics ( IGA )
Inhaled general anesthetics (IGA) undergo metabolism, biotransformation, and chemical breakdown that can generate toxic substances. Modern IGA are metabolized minimally compared to early generations of IGA and hence are more safe. Pharmacogenomics, age, gender, drug‐drug interaction, concomitant liver and kidney diseases can affect the metabolism and toxicity of IGA. Products of IGA metabolism can rarely induce immune‐mediated hepatotoxicity. Nephrotoxicity of IGA is related to inorganic fluoride, a product of IGA metabolism. There is growing evidence for the neurotoxicity of IGA, especially in the developing or immature brain. Lastly, IGA has complex interactions with the immune system, which may adversely affect susceptible patients.
- Top Cited PapersOpen Access
- 22 September 2015
- Published by Termedia Sp. z.o.o. in Anaesthesiology Intensive Therapy
- Vol. 47 (4) , 339-350
Tranexamic acid: a clinical review
Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings. Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings.
- 22 September 2015
- Published by Termedia Sp. z.o.o. in Anaesthesiology Intensive Therapy
- Vol. 47 (4) , 339-350
Top Cited PapersOpen AccessTranexamic acid: a clinical review
Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings. Blood loss and subsequent transfusions are associated with major morbidity and mortality. The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic surgery, liver surgery and solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases. The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. This review aims to help acute care physicians navigate through the clinical evidence available for TXA therapy, develop appropriate dose regimens whilst minimizing harm, as well as understand its broadening scope of applications. Many questions remain unanswered regarding other clinical effects of TXA such as anti-inflammatory response to cardiopulmonary bypass, the risk of thromboembolic events, adverse neurological effects such as seizures, and its morbidity and mortality, all of which necessitate further clinical trials on its usage and safety in various clinical settings.